First 3 runs free, then $50/run
    First 3 runs free, then $50/run

    Investment case

    Revolution Medicines, Inc.

    RVMD · 11 developments mapped · last assessed 2026-09-03

    Market Ontology has mapped 11 macro, policy, and market developments to Revolution Medicines, Inc. since 2026-08-26. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.

    Last close
    Unavailable
    No published quote
    Market cap
    Unavailable
    Equity value
    Diluted shares
    Unavailable
    Latest reported
    Sector
    Unavailable
    Listing
    Unavailable
    Filings
    Unavailable
    No published filing

    Valuation

    No validated run has been published for RVMD yet, so no modelled value is shown. The RVMD valuation is in the public catch-up queue.

    Subscribers do not wait for the weekly cycle: they run RVMD on demand, against live prices and the latest filings, and change any assumption the developments below move.

    Filed financials

    A validated filed-statement snapshot has not been published for RVMD. Missing data is not estimated or replaced with scenario assumptions.

    Current case

    • Strongest support

      NEJM Publishes Revolution Medicines Phase 1/2 Lung Cancer Data

      Direct positive clinical trial data publication in a prestigious journal (NEJM) for a key pipeline asset (darovasertib in RAS-mutant NSCLC), validating the company's pan-RAS inhibitor platform and increasing confidence in future commercialization.

      · Moves probability of technical success (pots) for darovasertib, peak sales estimates for darovasertib, discount rate (due to reduced risk)

    What changed, by assumption

    Probability of technical success (pots) for darovasertib
    • 2026-09-03NEJM Publishes Revolution Medicines Phase 1/2 Lung Cancer Data
    Probability of success for daraxonrasib
    • 2026-09-03Revolution Medicines Publishes Phase 1/2 Data for Daraxonrasib in NEJM with 42% ORR
    • 2026-09-03NEJM publishes Revolution Medicines Phase 1/2 data showing 42% ORR in NSCLC
    Probability of technical success (pots)
    • 2026-09-03Revolution Medicines Publishes Phase 1/2 Data for Daraxonrasib in NEJM
    Probability of success for rasonque
    • 2026-09-03NEJM Publishes Revolution Medicines Daraxonrasib NSCLC Data: 42% ORR, 16.0 Mo Survival
    Probability of technical success (pots) for daraxonrasib
    • 2026-09-03NEJM Publishes Revolution Medicines Phase 1/2 Data for Daraxonrasib in Lung Cancer

    Event impact log

    Full ledger →
    DateMechanismDirectionHorizonImpact
    2026-09-03NEJM Publishes Revolution Medicines Phase 1/2 Lung Cancer DataBullish1-3m0.90
    2026-09-03Revolution Medicines Publishes Phase 1/2 Data for Daraxonrasib in NEJM with 42% ORRBullish1-3m0.90
    2026-09-03Revolution Medicines Publishes Phase 1/2 Data for Daraxonrasib in NEJMBullish1-3m0.90
    2026-09-03NEJM Publishes Revolution Medicines Daraxonrasib NSCLC Data: 42% ORR, 16.0 Mo SurvivalBullish1-3m0.90
    2026-09-03NEJM publishes Revolution Medicines Phase 1/2 data showing 42% ORR in NSCLCBullish1-3m0.90
    2026-09-03NEJM Publishes Revolution Medicines Phase 1/2 Data for Daraxonrasib in Lung CancerBullish1-3m0.90
    2026-08-27FDA Approves Revolution Medicines' RASONQUE as First Broad RAS InhibitorBullish1-3m0.90
    2026-08-27FDA Approves Revolution Medicines RASONQUE in Pancreatic CancerBullish1-5y0.90
    2026-08-27FDA Approves Revolution Medicines' RASONQUE for Metastatic Pancreatic CancerBullish1-3m0.90
    2026-08-27FDA Approves Revolution Medicines RASONQUE for Metastatic Pancreatic AdenocarcinomaBullish1-3m0.90
    2026-08-26FDA Approves Revolution Medicines' RASONQUE as First Targeted RAS InhibitorBullish1-5y0.90